Dextera Surgical Inc. (NASDAQ:DXTR) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Dextera Surgical Inc. designs and manufactures proprietary stapling devices for surgical procedures. The company’s product consists of MicroCutter 5/80 use for transection and resection in urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the intestine and the transection of the appendix. Dextera Surgical Inc., formerly known as Cardica Inc., is headquartered in Redwood City, California. “

DXTR has been the topic of several other reports. Wedbush lowered their price objective on shares of Dextera Surgical from $3.50 to $0.70 and set an “outperform” rating on the stock in a research note on Wednesday, July 12th. Ladenburg Thalmann Financial Services started coverage on shares of Dextera Surgical in a research note on Wednesday, August 16th. They set a “buy” rating and a $0.80 price objective on the stock.

Shares of Dextera Surgical (NASDAQ DXTR) traded down 4.146% during midday trading on Tuesday, hitting $0.215. The stock had a trading volume of 2,939,915 shares. The firm’s market capitalization is $3.83 million. Dextera Surgical has a 1-year low of $0.17 and a 1-year high of $2.33. The company’s 50 day moving average price is $0.30 and its 200-day moving average price is $0.41.

Dextera Surgical (NASDAQ:DXTR) last released its quarterly earnings data on Tuesday, August 8th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.29). The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.03 million. Equities analysts predict that Dextera Surgical will post ($0.25) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/10/dextera-surgical-inc-dxtr-upgraded-to-hold-by-zacks-investment-research.html.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Broadfin Capital LLC grew its stake in Dextera Surgical by 64.7% in the 2nd quarter. Broadfin Capital LLC now owns 987,520 shares of the medical instruments supplier’s stock valued at $296,000 after buying an additional 388,080 shares during the last quarter. Virtu KCG Holdings LLC grew its stake in Dextera Surgical by 1,380.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 369,918 shares of the medical instruments supplier’s stock valued at $111,000 after buying an additional 344,933 shares during the last quarter. Finally, Perkins Capital Management Inc. acquired a new position in Dextera Surgical in the 2nd quarter valued at about $100,000. Institutional investors and hedge funds own 6.58% of the company’s stock.

Dextera Surgical Company Profile

Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Get a free copy of the Zacks research report on Dextera Surgical (DXTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.